Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug
Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public offering ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · finance
- [FINANCE] EFCC arrests ex-Skye Bank chairman over N36.54bn, $30m fraud allegations
- [FINANCE] EFCC arrests ex-Skye Bank chair Tunde Ayeni
- [FINANCE] Justice Department drops probe of Fed's Jerome Powell
- [FINANCE] Japanese Yen Forecast: USD/JPY Coils Below 160—Breakout Setup Builds - FOREX.com
- [FINANCE] Nasdaq and Tech continue to outperform – Dow Jones and US Stock Market Outlook - marketpulse.com
- [FINANCE] Tennessee bans crypto ATMs statewide, joining Indiana in fraud crackdown - The Block